Skip to main content

Featured

The CUSMA Countdown: 24 Days to a Trade Deadline That Could Hit Your Wallet

Canada's free trade deal with the U.S. hits a mandatory review milestone on July 1. With negotiations unresolved and Washington demanding changes, here's what it actually means for your groceries, your car, and your job. MoneySavings.ca Staff Canadian Money Brief June 7, 2026 5 min read What Is CUSMA and Why Does July 1 Matter? CUSMA — the Canada-United States-Mexico Agreement — is the trade deal that keeps the North American economy humming. It replaced NAFTA in 2020 and governs the movement of trillions of dollars in goods and services across the Canada-U.S. border every year. For Canadian consumers, it's largely invisible — until it isn't. Built into the agreement is a mandatory six-year joint review, and that clock expires on July 1, 2026 . By that date, all three countries must declare whether they want to renew the deal for another 16 years, trigger annual reviews, or walk away. Whatever they decide, CUSMA technically stays in force until 2036 — but the path chose...
Post a Comment
Read more

article

Labels

Revolutionary Gene Therapy Restores Hearing in Deaf Toddler

 

In a remarkable medical breakthrough, an 18-month-old toddler named Opal Sandy has regained her hearing thanks to a pioneering gene therapy trial. Born deaf due to a rare genetic condition affecting the OTOF gene, which is responsible for producing a protein essential for hearing, Opal’s prospects for natural hearing were bleak. However, the innovative treatment at Cambridge University Hospitals in England has opened up a world of sound for her.

The procedure involved the infusion of a working copy of the OTOF gene into Opal’s right ear, a process that took a mere 16 minutes. Remarkably, within weeks, Opal began responding to loud noises, and after 24 weeks, she could hear whispers, indicating a near-normal level of hearing restoration.

Opal’s case is part of the Chord trial, which is recruiting more children from the UK, Spain, and the US to undergo similar treatment. The trial is being closely monitored, with participants followed up for five years to assess the long-term efficacy and safety of the therapy.

The success of this gene therapy is a beacon of hope for many suffering from genetic deafness, signaling the dawn of a new era in medical science where conditions once thought incurable are now within the realm of treatment. Opal’s story is not just a personal victory; it’s a milestone in genetic medicine, showcasing the incredible potential of gene therapy to change lives.

Labels:

Comments

Post a Comment